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In a recent issue of JASN, Lee and colleagues [1] pre-
sented the results of a simulation model estimating the
cost-effectiveness of different modalities of centre-based
dialysis, increasing frequency and/or duration.
Their simulation shows that this intensified approach,
even with—according to the authors—rather conservative
assumptions about its benefit is associated with poor cost-
effectiveness. None of the simulations resulted in a cost per
quality adjusted life year (QALY) below$75000.Generally,
the societal threshold for the willingness to pay for gaining
1 QALY is around $50 000 as the authors confirm.
In other words, the extra money spent on the increased
frequency and/or increased duration does not result in a pro-
portionally acceptable health benefit. Spending this money
elsewhere (for instance on better prevention of nephropathy,
or on alternative non-centre-based types of dialysis) would
bring much more benefit to society.
One could moreover argue that the assumptions are not
that conservative at all: the rare evidence existing about this
intensified approach was not able to show any difference
in frequency or duration of hospitalizations or in compli-
cations. Yet, a 32% reduction in mortality and a gain of 2
QALYs for the ‘best’ scenario (six times per week, 4.5 h per
session) was assumed, which seems rather optimistic. Also,
it is not clear where the data to calculate the QALY weights
were obtained from and whether the increased frequency
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and duration were associated with a (negative) impact on
quality of life.
But regardless of these comments, there is clearly no
economic case for intensified dialysis, based on the current
assumptions. A possibility is to make efforts to reduce the
cost per session. For instance, the cost of five times per
week at 2.5 h per session should decrease by 43% in order
to obtain a break-even compared to thrice a week in Lee
et al. [1]. But even if that would be possible by increasing
the efficiency dramatically and decreasing the cost of staff
and material, this would also have an effect on the base case
(three times per week, 3.5 h per session), a decrease that
should also be taken into account.
The authors developed a decisional framework in which
several input data needed to be assumed and thenweremade
subject to extensive sensitivity analysis. Despite some criti-
cisms on the type of modelling that Lee et al. [1] performed,
because it is not based on hard evidence, it should be en-
couraged, because it provides an excellent framework to
test scenarios and answer to several ‘what if’ questions,
thereby increasing our knowledge about the condition and
its management [2].
Some would also argue that even if the cost-effectiveness
is not very good, we are dealing here with people’s lives.
In other words: ‘are we going to deny better care to these
people for the reason of cost?’ I would rather talk about
value than about cost. The real question is what is the value
of this intensified care? Is it value for money? After all,
the goal of health care is to produce health [3], and in any
production process, one needs to aim for being productive,
i.e. to produce the most possible output (here health) with
the invested money. When a given production process is
not productive, then we must not undertake it, because we
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spend money that could have been better spent elsewhere.
In other words, proceeding with such not cost-effective care
means denying better health care to other patients and to
society.
How would the results of this study look like in a
European setting? First, in contrast to our general belief,
cost of dialysis in Europe may not be much lower. For in-
stance, Van Biesen et al. [4] documented for Belgium a cost
for in-hospital dialysis per year of€53 000 versus€32 000
for peritoneal dialysis, while in Lee et al., the cost in the
first year was $64 000. Dialysis as such is borderline cost-
effective in Europe as shown by Salonen et al. [5], with
a cost per QALY of ±€40 000. Hence, one could argue
that the incremental cost-effectiveness of intensified dial-
ysis (the extra cost divided by the extra QALYs versus the
base case of three times per week) should remain below
that value. Given the above, I doubt it.
Hence, if I were a payer (whether it would be an in-
surer or NHS responsible) I would not pay for this care,
based on these results. I would invest much more in al-
ternative non-in-centre based types of dialysis. I could of
course request additional information and allow the use of
intensified dialysis in a research setting, hence reimbursing
it conditionally upon more evidence to be expected. This
will likely reduce uncertainty, but this also costs money. A
possible way out is to calculate the value of information
beforehand. This method, based on modelling techniques,
focuses on the value of obtaining further information that
will reduce uncertainty [6]. If that value turns out to be
lower than the cost of this further research, one may de-
cide not to undertake this further research. Calculating this
value of information may perhaps be a new challenge for
Lee et al. [1].
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Summary
The discovery that fibroblast growth factor 23 (FGF-23)
intimately connects skeletal biology and systemic min-
eral balance is one of the major breakthroughs of the last
decade in renal medicine. In a recent observational study
by Gutie´rrez et al. [2] high FGF-23 levels emerged as a
much strong predictor of death and the predictive power
of this peptide was maintained even when this relation-
ship was analysed within serum phosphate levels quartiles.
Because FGF-23 levels can be lowered by reducing phos-
phate intake, provided that the FGF-23-death link is causal,
the perspective arises that patients with normal phosphate
C© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
